Department of Primary Care, Regional Neurogenetic Centre (CRN), ASP Catanzaro, 88046 Lamezia Terme, Italy.
Association for Neurogenetic Research (ARN), 88046 Lamezia Terme, Italy.
Curr Oncol. 2022 Oct 27;29(11):8103-8120. doi: 10.3390/curroncol29110640.
Breast cancer represents the most common type of cancer and is the leading cause of death due to cancer among women. Thus, the prevention and early diagnosis of breast cancer is of primary urgency, as well as the development of new treatments able to improve its prognosis. Nerve Growth Factor (NGF) is a neurotrophic factor involved in the regulation of neuronal functions through the binding of the Tropomyosin receptor kinase A (TrkA) and the Nerve Growth Factor receptor or Pan-Neurotrophin Receptor 75 (NGFR/p75NTR). In addition, its precursor (pro-NGF) can extert biological activity by forming a trimeric complex with NGFR/p75NTR and sortilin, or by binding to TrkA receptors with low affinity. Several examples of in vitro and in vivo evidence show that NGF is both synthesized and released by breast cancer cells, and has mitogen, antiapoptotic and angiogenic effects on these cells through the activation of different signaling cascades that involve TrkA and NGFR/p75NTR receptors. Conversely, pro-NGF signaling has been related to breast cancer invasion and metastasis. Other studies suggested that NGF and its receptors could represent a good diagnostic and prognostic tool, as well as promising therapeutic targets for breast cancer. In this paper, we comprehensively summarize and systematically review the current experimental evidence on this topic. INPLASY ID: INPLASY2022100017.
乳腺癌是最常见的癌症类型，也是女性癌症死亡的主要原因。因此，预防和早期诊断乳腺癌至关重要，同时也需要开发新的治疗方法来改善其预后。神经生长因子（NGF）是一种神经营养因子，通过与原肌球蛋白受体激酶 A（TrkA）和神经生长因子受体或泛神经生长因子受体 75（NGFR/p75NTR）结合，调节神经元功能。此外，其前体（pro-NGF）可以通过与 NGFR/p75NTR 和分选素形成三聚体复合物，或通过与低亲和力的 TrkA 受体结合发挥生物学活性。一些体外和体内证据表明，NGF 由乳腺癌细胞合成和释放，并通过激活涉及 TrkA 和 NGFR/p75NTR 受体的不同信号级联反应，对这些细胞具有有丝分裂原、抗凋亡和血管生成作用。相反，pro-NGF 信号与乳腺癌的侵袭和转移有关。其他研究表明，NGF 及其受体可能是一种良好的诊断和预后工具，也是治疗乳腺癌的有前途的靶点。本文全面总结和系统回顾了这一主题的现有实验证据。INPLASY ID: INPLASY2022100017.
